Two glioblastoma patients treated with Temferon have lived 3 years post-surgery; one had no progression, the other stabilized ...

Genitourinary Tumor Study Ongoing with Active Screening and Enrollment. MILAN and NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-o ...

Brain macrophages serve diversified niches in the brain to maintain the organ’s homeostasis, and can play pathogenic roles in age-related brain disease. Hoping to one day replace dysfunctional ...

Tempus AI Inc (NASDAQ:TEM) shares are moving higher Monday after the company introduced a new program to monitor immunotherapy response for patients with advanced cancer.

Efficacy of macrophage checkpoint Clever-1 inhibition with bexmarilimab plus azacitidine in myelodysplastic syndrome: Results from the ph1/2 BEXMAB study.

Research identifies how viral respiratory infection damages macrophages and suggests treatment with a pre-existing FDA approved drug.

Researchers at National Jewish Health and colleagues have completed the first study comparing lung macrophages in multiple models of lung injury. The research indicates that macrophages previously ...

The engineered macrophages were well tolerated and outperformed non-engineered cells in all models. Based on the promising findings, the company is committed to advancing its liver fibrosis program.

Study identifies pro-inflammatory macrophage subtype with distinct genetic features in inflamed joints of RA patients.

Early intermittent hyperlipidemia significantly accelerates atherosclerosis by disrupting macrophage function, highlighting the need for early cholesterol management.

The Food and Drug Administration has granted Fast Track designation to emapalumab-lzsg for the treatment of macrophage activation syndrome.

A macrophages-based immunotherapy of solid tumors microenvironment: Preliminary results of the TEM-GBM_01 study [abstract]. In: Proceedings of the American Association for Cancer Research Annual ...